United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2017_register executive 2017-11-29 article Notices D09002ee1c7ef44bb D09002ee1c7ef457e United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency The National Heart, Lung, and Blood Institute ("NHLBI"), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to T-Cure Bioscience, Inc. located in Thousand Oaks, California and incorporated under the laws of Delaware. 82 FR 56622 https://www.govinfo.gov/app/details/FR-2017-11-29/2017-25743 2017-25743 fr29no17-41 4140-01-P https://www.govinfo.gov/app/details/FR-2017-11-29/2017-25743 https://www.govinfo.gov/content/pkg/FR-2017-11-29/html/2017-25743.htm https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25743.pdf 2 p. 56622 56623 82 FR 56622 Prospective Grant of Exclusive Patent License: T-Cells Transduced with HLA A11 Restricted CT-RCC HERV-E Reactive T-Cell Receptors for the Treatment of Renal Cell Carcinoma; Federal Register Vol. 82, Issue NOTICE 2017-25743 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2017-12-14 4140-01-P 2017-25743 Notice.

The National Heart, Lung, and Blood Institute ("NHLBI"), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to T-Cure Bioscience, Inc. located in Thousand Oaks, California and incorporated under the laws of Delaware.

Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before December 14, 2017 will be considered. Prospective Grants of Exclusive Patent Licenses: T-Cells Transduced with HLA A11 Restricted CT-RCC HERV-E Reactive T-Cell Receptors for Treatment of Renal Cell Carcinoma , thalhamc@mail.nih.gov Vol. 82, no. 228 Office of the Federal Register, National Archives and Records Administration 2017-11-29 continuing daily deposited born digital 180 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2017-11-29 P0b002ee197a22c9d 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr29no17 https://www.govinfo.gov/app/details/FR-2017-11-29 https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/FR-2017-11-29.pdf https://www.govinfo.gov/content/pkg/FR-2017-11-29/xml/FR-2017-11-29.xml fdlp 56529 56701 DGPO 2017-11-29 2024-06-01 FR-2017-11-29 machine generated eng FR FR-2017-11-29 82 228